ACE inhibitors and ARBs are the best first-line blood pressure medications for kidney disease. These two drug classes don’t just lower blood pressure; they protect the kidneys through mechanisms that go beyond what other blood pressure medications can do. Your specific situation, including how much kidney function you’ve lost and whether you have diabetes, determines which combination of drugs will work best for you.
Why ACE Inhibitors and ARBs Come First
ACE inhibitors (like lisinopril and ramipril) and ARBs (like losartan and valsartan) work by blocking the renin-angiotensin-aldosterone system, a hormonal pathway that regulates blood pressure and fluid balance. What makes them uniquely valuable for kidney disease is what they do inside the kidney itself. They relax the tiny blood vessel leaving each filtering unit in the kidney, which reduces the pressure inside that filter. Less pressure means less protein leaking into your urine, less inflammation, and less scarring over time.
This protein-lowering effect is a big deal. Protein in the urine (albuminuria) isn’t just a marker of kidney damage; it actively drives further damage. In studies of children with chronic kidney disease, ramipril reduced proteinuria by an average of 43.5%, and that early reduction was linked to better long-term kidney function. The same principle applies in adults. Reducing proteinuria is now considered a core treatment target, not just a number to watch.
The two classes perform similarly in terms of kidney protection, but they should not be used together. Combining an ACE inhibitor with an ARB increases the risk of dangerous side effects, particularly high potassium and acute kidney injury, without meaningful added benefit.
High Potassium: The Main Risk to Watch
The most important side effect of ACE inhibitors and ARBs in kidney disease is hyperkalemia, or elevated potassium levels. Clinical trial data puts the risk between 2% and 10% in people with hypertension, heart failure, or CKD. In real-world practice, the numbers are higher. Among patients with severely reduced kidney function (GFR below 30) who had regular blood tests, over 60% had at least one elevated potassium reading over a three-year period.
ACE inhibitors carry a higher potassium risk than ARBs. In a large health-system analysis, ACE inhibitors were associated with a 54% increased risk of potassium rising above 5 mEq/L, while ARBs showed only a 7% increase. For the more dangerous threshold of 5.5 mEq/L, ACE inhibitors remained strongly associated with risk, while ARBs showed no statistically significant increase. This means switching from an ACE inhibitor to an ARB is a reasonable strategy if potassium becomes a problem.
When potassium does spike, the most common responses are rechecking the level, adjusting medications, or adding a diuretic that helps the body shed potassium. In about one-quarter of cases, the ACE inhibitor or ARB is stopped altogether. But because these drugs are so important for kidney protection, the goal is usually to find a way to keep using them, whether through dietary potassium restriction, dose reduction, or adding a diuretic.
A Small Rise in Creatinine Is Normal
When you start an ACE inhibitor or ARB, your creatinine level (a blood marker of kidney function) will often bump up slightly. This can be alarming, but it’s expected. A creatinine increase of 25% to 30% above your baseline is considered acceptable and actually reflects the drug doing its job of reducing pressure inside the kidney’s filters. If creatinine rises more than that, your doctor will likely recheck it and possibly adjust the dose.
SGLT2 Inhibitors: A Powerful Addition
SGLT2 inhibitors (like dapagliflozin, empagliflozin, and canagliflozin) were originally developed for diabetes, but they’ve proven to be genuinely transformative for kidney disease, even in people without diabetes. Three landmark trials, CREDENCE, DAPA-CKD, and EMPA-KIDNEY, showed that these drugs significantly reduce the risk of kidney disease progression, kidney failure, and major cardiovascular events when added on top of ACE inhibitors or ARBs.
In a meta-analysis of hypertensive patients with CKD, SGLT2 inhibitors reduced the risk of kidney-specific outcomes by 30% compared to placebo. They also lowered cardiovascular events by about 21%. These benefits came on top of standard therapy, meaning patients were already taking an ACE inhibitor or ARB. The blood pressure effect of SGLT2 inhibitors is modest, typically a 3 to 5 mmHg drop in systolic pressure, but their kidney protection goes well beyond what that small pressure change would explain.
The mechanism is complementary to what ACE inhibitors and ARBs do. While those drugs relax the blood vessel leaving the kidney’s filter, SGLT2 inhibitors tighten the vessel entering it. Together, they reduce filtering pressure from both sides. Current guidelines now recommend SGLT2 inhibitors as part of standard therapy for most people with CKD, making the combination of an ACE inhibitor (or ARB) plus an SGLT2 inhibitor the new baseline treatment for many patients.
Finerenone for CKD With Type 2 Diabetes
Finerenone is a newer medication that blocks a different hormonal receptor involved in kidney inflammation and scarring. In a trial of nearly 5,700 patients with CKD and type 2 diabetes, all of whom were already on maximum-dose ACE inhibitors or ARBs with well-controlled blood sugar and blood pressure, finerenone reduced the risk of kidney failure, significant kidney function decline, or death from kidney causes by 18% over about two and a half years. It also reduced cardiovascular events by 14%.
This is notable because the patients in this trial were already on optimized therapy. Finerenone provided additional protection on top of everything else. It’s not a first-line blood pressure drug, but for people with CKD and type 2 diabetes who remain at high risk despite standard treatment, it adds a meaningful layer of protection.
Calcium Channel Blockers: Not All Equal
Calcium channel blockers are commonly used to lower blood pressure, but their effect on the kidneys depends on which type you take. There are two subclasses, and they behave very differently inside the kidney.
Nondihydropyridine calcium channel blockers (diltiazem and verapamil) reduce pressure inside the kidney’s filters and consistently lower proteinuria. In one head-to-head trial of patients with type 2 diabetes and significant proteinuria, diltiazem reduced protein in the urine by 57% more than nifedipine, a dihydropyridine, despite both drugs lowering blood pressure equally.
Dihydropyridine calcium channel blockers (amlodipine and nifedipine) are effective at lowering blood pressure but do not reduce the pressure inside the kidney’s filters. They can even increase proteinuria when used alone. If you’re already on an ACE inhibitor or ARB, adding amlodipine is generally fine because the underlying kidney protection is already in place. But as a standalone choice for someone with proteinuric kidney disease, nondihydropyridines are the better option in this class.
When Diuretics Are Needed
Many people with kidney disease retain extra fluid, making diuretics an important part of blood pressure control. The type of diuretic that works depends on your level of kidney function.
- GFR 30 or above (stages 1 through 3): Thiazide diuretics (like hydrochlorothiazide or chlorthalidone) work effectively and are typically given once daily.
- GFR below 30 (stages 4 and 5): Thiazide diuretics lose their effectiveness at this level of kidney function. Loop diuretics (like furosemide) are used instead, often given once or twice daily.
- Exception: Metolazone, a thiazide-like diuretic, retains effectiveness even below a GFR of 30 and is sometimes used in more advanced kidney disease.
Diuretics also help counteract the potassium-raising effect of ACE inhibitors and ARBs. Loop and thiazide diuretics were associated with a 40% decreased risk of elevated potassium, making them useful partners in a kidney-focused regimen.
One Important Contraindication
ACE inhibitors and ARBs should not be used in people with bilateral renal artery stenosis, a condition where the arteries supplying both kidneys are narrowed. Because these drugs work by relaxing the blood vessel leaving the kidney’s filter, they can cause a dramatic drop in filtering pressure when the blood supply coming in is already restricted. This can lead to acute kidney failure. If you have known narrowing of one or both kidney arteries, your doctor will choose a different medication class entirely.